More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to…
eTurboNews artikel hanya untuk pelanggan. Berlangganan adalah KONSULTASI.
Pelanggan masuk di sini Klik di sini untuk berlangganan GRATIS
Pelanggan masuk di sini Klik di sini untuk berlangganan GRATIS
APA YANG PERLU DIPERHATIKAN DARI PASAL INI:
- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.
- ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting.
- Lebrikizumab, an investigational IL-13 inhibitor, also led to….
